Meriofert (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

The luteinising hormone (LH) and follicle‑stimulating hormone (FSH) in Meriofert bind to their respective receptors on ovarian cells. This activates intracellular signalling pathways that promote follicular maturation, estrogen production, and the final LH surge that triggers the release of a mature egg, facilitating conception.

The dose of Meriofert is individualized by the treating physician based on the patient’s ovarian reserve, response to prior stimulation, and the specific assisted reproductive protocol. Only a qualified healthcare professional should determine the appropriate dosing schedule.

Meriofert is intended for use before conception to induce ovulation and is not recommended for use during an established pregnancy. Safety data for breastfeeding are limited, and the medication should only be used if the benefits outweigh potential risks, as determined by a healthcare provider.

To request Meriofert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and necessary import documentation.

Meriofert combines both LH and FSH in a single injectable formulation, which can simplify treatment regimens compared with using separate LH and FSH preparations. This dual‑action approach may improve coordination of follicular development and ovulation, but the choice of product depends on individual patient characteristics and clinician preference.

Meriofert should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any product that appears discoloured or contains particles.

Meriofert is administered by a qualified healthcare professional via intramuscular or subcutaneous injection, typically in a clinical setting. The injection site is usually the thigh or abdomen, and the exact technique follows the prescribing information and local clinical guidelines.

The most serious risks include severe ovarian hyperstimulation syndrome, which can cause rapid weight gain, abdominal pain, and fluid accumulation, as well as rare allergic reactions such as anaphylaxis. Prompt medical attention is required if any signs of these conditions develop.

Meriofert should not be used by individuals with known hypersensitivity to any of its components, those with confirmed pregnancy, or patients with uncontrolled endocrine disorders that could exacerbate ovarian response. A thorough medical evaluation is required before initiating therapy.